ACP
ZSAN

Acuta Capital Partners’s Zosano Pharma Corporation ZSAN Stock Holding History

Acuta Capital Partners’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-105
Closed -$292K – 77
2015
Q3 		$292K Sell
105
-20
-16% -$112K 0.17% 56
2015
Q2 		$632K Buy
125
+94
+303% +$581K 0.39% 43
2015
Q1 		$222K Buy
+31
New +$233K 0.19% 49

Other funds holding ZSAN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Acuta Capital Partners's ZSAN Position: Q4 2015 in Review

Acuta Capital Partners sold out of Zosano Pharma Corporation (ZSAN) in Q4 2015, closing a stake of 105 shares — an estimated $292K sold.

Acuta Capital Partners first reported a position in ZSAN in Q1 2015 and held it in 3 quarters. The position peaked at $632K in Q2 2015. 13 funds tracked by Wall St. Rank hold ZSAN as of Q4 2015.

  • Acuta Capital Partners reported no remaining Zosano Pharma Corporation position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 105 Zosano Pharma Corporation shares in Q4 2015, an estimated $292K.
  • Acuta Capital Partners first reported a position in Zosano Pharma Corporation in Q1 2015 and held it in 3 quarters.
  • Acuta Capital Partners's Zosano Pharma Corporation position peaked at $632K in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.